Hexarelin Dosage Guide: How Much Should You Take? (2026)

Key Takeaways

• Standard dosage range: 100-200 mcg administered subcutaneously 1-3 times daily, with most protocols using 100 mcg twice daily^[1]
• Administration method: Subcutaneous injection using 29-31 gauge insulin syringes, rotated between abdomen, thigh, and upper arm sites
• Typical cycle length: 8-16 weeks with mandatory 4-8 week breaks to prevent desensitization of growth hormone secretagogue receptors^[2]
• Half-life: Approximately 70 minutes, requiring multiple daily doses for sustained growth hormone elevation^[3]
• Bioavailability: 95-98% via subcutaneous injection, significantly higher than oral forms (5-10%)^[1]
• Regulatory status: Research peptide only - not FDA-approved for human therapeutic use
• Medical supervision: Required due to potential cardiovascular effects and growth hormone axis disruption

How Hexarelin Works in the Body

Hexarelin functions as a synthetic growth hormone-releasing peptide (GHRP) that binds to both growth hormone secretagogue receptors (GHSR) and the cardiac-specific CD36 receptor.^[4] This dual receptor activation distinguishes hexarelin from other GHRPs and influences its dosing requirements. The peptide's molecular weight of 887.04 Da allows for efficient subcutaneous absorption, achieving peak plasma concentrations within 15-30 minutes post-injection.^[3]

The peptide's relatively short half-life of 70 minutes necessitates multiple daily administrations to maintain therapeutic growth hormone elevation.^[3] Clinical studies demonstrate that hexarelin stimulates growth hormone release in a dose-dependent manner up to approximately 100 mcg, with higher doses producing diminishing returns and increased side effect risk.^[1]

"Hexarelin exhibits significant protection against organ injury in models of ischemia/reperfusion-induced injury, suggesting therapeutic potential beyond growth hormone release."^[5]

Unlike endogenous ghrelin, hexarelin maintains chemical stability at room temperature for 24-48 hours and demonstrates resistance to enzymatic degradation, contributing to its consistent bioavailability profile.^[4] This stability allows for precise dosing protocols, though proper storage at 36-46°F (2-8°C) remains essential for long-term potency maintenance.

Standard Hexarelin Dosage Ranges (By Form)

Subcutaneous administration represents the preferred delivery method due to its superior bioavailability of 95-98% and predictable pharmacokinetic profile.^[1] The subcutaneous route allows for self-administration using standard 29-31 gauge insulin syringes, making it practical for outpatient protocols. Peak plasma concentrations occur 15-30 minutes post-injection, with growth hormone elevation lasting 2-4 hours.^[3]

Intramuscular injection achieves slightly lower bioavailability (90-95%) but provides more sustained absorption over 4-6 hours.^[1] This route requires longer needles (1-1.5 inches) and carries higher injection site reaction risk. Most clinical protocols reserve intramuscular administration for patients with subcutaneous injection site limitations or specific absorption requirements.

Oral hexarelin formulations demonstrate poor bioavailability (5-10%) due to first-pass hepatic metabolism and peptide degradation in gastric acid.^[1] Doses of 2-5 mg are required to achieve plasma levels equivalent to 100-200 mcg subcutaneous administration, making oral forms cost-prohibitive and impractical for most applications.

Hexarelin Dosage by Use Case

Growth Hormone Optimization

Standard protocols utilize 100 mcg subcutaneously twice daily, administered upon waking and before bedtime to align with natural growth hormone pulsatile release.^[2] This dosing schedule maintains elevated growth hormone levels for 8-12 hours daily while allowing receptor recovery between doses. Clinical experience suggests this protocol produces 2-4 fold increases in baseline growth hormone levels within 7-14 days.^[1]

Advanced protocols may escalate to 200 mcg twice daily after 4-6 weeks of tolerance assessment, though doses exceeding 300 mcg daily rarely provide additional benefit and increase side effect risk.^[2] Many specialized clinics implement a 5-day-on, 2-day-off schedule to prevent receptor desensitization during extended treatment periods.

Muscle Recovery and Performance

Athletic recovery protocols typically employ 100-150 mcg subcutaneously within 30 minutes post-workout, capitalizing on the exercise-induced growth hormone response window.^[1] Additional morning doses of 100 mcg may be added for athletes undergoing intensive training phases lasting 8-12 weeks. This timing maximizes protein synthesis and glycogen replenishment during the critical post-exercise recovery period.

Competitive athletes often cycle hexarelin in 6-week blocks with 2-week washout periods to maintain receptor sensitivity throughout training seasons.^[2] Doses exceeding 200 mcg per administration provide minimal additional recovery benefit while increasing detection risk in tested sports.

Cardiovascular Protection

Emerging protocols for cardiovascular protection utilize lower doses of 50-100 mcg once daily, targeting the CD36 receptor pathway rather than maximal growth hormone stimulation.^[4] Research indicates that hexarelin's cardioprotective effects may be mediated through non-GHSR mechanisms, allowing for lower dosing strategies with reduced systemic exposure.^[5]

These protocols typically extend 12-16 weeks with careful cardiac monitoring, as long-term cardiovascular effects remain incompletely characterized in human populations.^[4] Many cardiology-focused clinics require baseline echocardiograms and quarterly cardiac assessments during hexarelin therapy.

Anti-Aging and Longevity

Anti-aging protocols commonly employ 100 mcg subcutaneously once daily, administered 2-3 hours before bedtime to enhance nocturnal growth hormone release.^[2] This approach mimics natural growth hormone secretion patterns while minimizing daytime side effects such as water retention and glucose intolerance.

Extended anti-aging protocols may continue 16-24 weeks with mandatory 8-12 week breaks to prevent hypothalamic-pituitary-adrenal axis suppression.^[1] Doses typically remain conservative (50-100 mcg daily) to balance longevity benefits with long-term safety considerations in older adult populations.

Titration Protocol: How to Ramp Up Safely

The initial 50 mcg dose allows for tolerance assessment while minimizing risk of severe hypoglycemia or cardiovascular effects.^[1] Patients should monitor blood glucose levels during the first week, as hexarelin can enhance insulin sensitivity and glucose uptake in muscle tissue. Starting doses below 50 mcg rarely produce measurable growth hormone elevation and may delay therapeutic benefits.

Escalation to 100 mcg represents the minimum effective dose for most therapeutic applications, producing 2-3 fold increases in growth hormone levels within 1-2 hours post-injection.^[3] Patients typically report improved sleep quality and exercise recovery within 7-10 days at this dose level. Side effects at 100 mcg remain minimal in healthy adults, consisting primarily of mild injection site reactions and occasional flushing.

The transition to twice-daily dosing (100 mcg AM and PM) provides more consistent growth hormone elevation throughout the 24-hour cycle.^[2] Morning doses should be administered upon waking on an empty stomach, while evening doses are optimally timed 2-3 hours before bedtime to avoid sleep disruption from growth hormone-induced cortisol release.

Doses exceeding 200 mcg twice daily (400 mcg total daily) rarely provide additional therapeutic benefit and significantly increase the risk of glucose intolerance, water retention, and joint pain.^[1] Most clinical protocols establish 300-400 mcg daily as the maximum safe upper limit for healthy adults under medical supervision.

How Long Should You Take Hexarelin?

Typical hexarelin cycles range from 8-16 weeks, with most clinical protocols utilizing 12-week treatment periods followed by mandatory 4-8 week breaks.^[2] This cycling approach prevents desensitization of growth hormone secretagogue receptors and maintains therapeutic efficacy over multiple treatment courses. Continuous use beyond 16 weeks often results in diminished growth hormone response and increased side effect frequency.

During weeks 1-2, patients commonly experience initial adaptation effects including mild fatigue, increased appetite, and subtle changes in sleep patterns.^[1] These effects typically resolve as the body adjusts to elevated growth hormone levels. Weeks 2-4 mark the period of optimal therapeutic response, with maximal improvements in recovery, body composition, and energy levels.

The 6-12 week timeframe represents the sustained benefit phase, where therapeutic effects plateau and maintain consistent levels.^[2] Patients report stable improvements in muscle recovery, sleep quality, and overall well-being during this period. Laboratory monitoring typically shows sustained elevation of IGF-1 levels 50-100% above baseline values.

Beyond 12 weeks, therapeutic benefits often begin to diminish due to receptor downregulation and potential suppression of endogenous growth hormone release.^[1] Week 16 marks the recommended maximum continuous treatment duration for most protocols, after which a mandatory washout period allows receptor resensitization and hypothalamic-pituitary axis recovery.

Abrupt discontinuation of hexarelin after extended use (>8 weeks) may result in temporary growth hormone deficiency symptoms including fatigue, decreased exercise tolerance, and mood changes lasting 2-4 weeks.^[2] Gradual tapering over 7-14 days (reducing dose by 50% weekly) can minimize withdrawal effects and ease the transition off therapy.

Administration Protocol: How to Inject Hexarelin

Proper hexarelin injection technique requires 29-31 gauge insulin syringes with 1/2-inch needles for subcutaneous administration.^[1] The 29-gauge needle provides optimal balance between injection comfort and accurate dose delivery, while 31-gauge needles may be preferred for patients with needle anxiety or frequent injection schedules. Syringe volume should accommodate the prescribed dose plus 10-20% overfill to ensure complete dose delivery.

Injection Site Selection and Rotation

Primary injection sites include the abdomen (2 inches from the navel in any direction), anterior thigh (outer middle third), and posterior upper arm (triceps region).^[1] The abdomen provides the most consistent absorption due to abundant subcutaneous tissue and reliable blood flow patterns. Thigh injections offer convenience for self-administration but may show slightly slower absorption rates.

Site rotation follows a systematic pattern to prevent lipodystrophy and maintain consistent absorption.^[1] A typical rotation schedule involves 8-12 distinct injection sites within each anatomical region, using each site once before returning to previously used locations. Minimum spacing of 1 inch between injection sites prevents tissue damage and ensures optimal healing between injections.

Step-by-Step Injection Process

1. Reconstitution preparation: If using lyophilized hexarelin, reconstitute with bacteriostatic water at a 1:1 ratio (1 mL water per 1 mg peptide) for optimal stability.^[3]
2. Hand hygiene: Wash hands thoroughly with soap and water for 20 seconds, then sanitize with 70% isopropyl alcohol.
3. Site preparation: Clean injection site with alcohol swab in circular motion from center outward, allow to air dry for 30 seconds.
4. Dose drawing: Insert needle into vial, invert, and slowly draw prescribed dose plus 10% overfill to account for dead space.
5. Air bubble removal: Tap syringe to collect air bubbles, slowly push plunger to expel air while maintaining dose accuracy.
6. Injection technique: Pinch skin fold, insert needle at 45-90° angle depending on subcutaneous tissue thickness.
7. Dose delivery: Slowly inject over 5-10 seconds to minimize tissue trauma and ensure complete absorption.
8. Needle withdrawal: Remove needle quickly, apply gentle pressure with alcohol swab for 10-15 seconds.
9. Disposal: Place used syringe in sharps container immediately after use.
10. Documentation: Record injection site, time, and any reactions in treatment log.

Optimal Timing and Storage

Hexarelin injections should be administered on an empty stomach, with at least 2 hours between meals and injection to maximize absorption.^[1] Morning doses are optimally timed upon waking, while evening doses should occur 2-3 hours before bedtime to align with natural growth hormone release patterns. Consistency in injection timing helps maintain stable plasma levels and therapeutic efficacy.

Reconstituted hexarelin requires refrigeration at 36-46°F (2-8°C) and maintains potency for 14-21 days when stored properly.^[3] Lyophilized powder remains stable at room temperature for 3-6 months but should be refrigerated for long-term storage exceeding 6 months. Avoid freezing, which can denature the peptide structure and reduce biological activity.

For detailed reconstitution instructions, refer to our comprehensive peptide reconstitution guide which covers sterile technique, mixing ratios, and storage requirements for various peptide formulations.

Stacking Hexarelin for Enhanced Results

Hexarelin + CJC-1295 DAC Stack

The combination of hexarelin (100-150 mcg twice daily) with CJC-1295 DAC (2-3 mg twice weekly) represents one of the most studied growth hormone optimization protocols.^[2] This stack leverages hexarelin's rapid growth hormone release with CJC-1295's sustained growth hormone-releasing hormone (GHRH) elevation, producing synergistic effects on IGF-1 production and muscle protein synthesis.

Typical dosing involves hexarelin administration 30 minutes before CJC-1295 injection on stack days (typically Monday and Thursday), with standalone hexarelin doses on non-CJC days.^[1] This protocol maintains consistent growth hormone elevation while preventing receptor desensitization through varied stimulation patterns. Clinical experience suggests 20-30% greater IGF-1 elevation compared to either peptide alone.

Hexarelin + Ipamorelin Combination

Conservative protocols often combine hexarelin (50-100 mcg) with ipamorelin (200-300 mcg) for balanced growth hormone stimulation with reduced side effect risk.^[2] Ipamorelin's selective GHSR activation complements hexarelin's broader receptor profile, potentially reducing cortisol elevation and glucose intolerance associated with higher hexarelin doses.

This combination typically utilizes 1:2 or 1:3 hexarelin-to-ipamorelin ratios, administered simultaneously via subcutaneous injection.^[1] The stack provides sustained growth hormone elevation for 4-6 hours while maintaining favorable side effect profiles suitable for long-term use in anti-aging applications.

Hexarelin + Sermorelin Protocol

Advanced protocols may incorporate hexarelin (100 mcg) with sermorelin (2-3 mg) for comprehensive growth hormone axis stimulation.^[2] This combination targets both growth hormone release (hexarelin) and growth hormone-releasing hormone production (sermorelin), creating a more physiologic stimulation pattern that mimics natural growth hormone pulsatility.

Sermorelin's longer half-life (8-12 minutes vs. hexarelin's 70 minutes) allows for less frequent dosing, typically once daily in the evening with twice-daily hexarelin administration.^[3] This protocol requires careful monitoring due to potential for excessive growth hormone elevation and associated metabolic effects.

Factors That Affect Your Hexarelin Dosage

Body Weight and Composition

Hexarelin dosing typically follows a weight-based calculation of 1-2 mcg per kilogram of body weight for standard protocols, though fixed dosing (100-200 mcg) remains more common in clinical practice.^[1] Patients weighing less than 60 kg may require dose reductions to 75-100 mcg to prevent excessive growth hormone elevation, while individuals exceeding 100 kg may benefit from doses up to 250 mcg per administration.

Body fat percentage significantly influences hexarelin pharmacokinetics, with higher adiposity correlating with improved subcutaneous absorption but potentially reduced growth hormone responsiveness.^[2] Patients with body fat percentages exceeding 25% may require 4-6 weeks of treatment before observing significant therapeutic benefits, compared to 2-3 weeks in leaner individuals.

Age-Related Dosing Considerations

Adults over 65 years typically require 25-50% dose reductions due to altered pharmacokinetics and increased sensitivity to growth hormone effects.^[1] Starting doses of 50 mcg once daily with gradual escalation over 4-6 weeks help minimize side effects while maintaining therapeutic efficacy. Elderly patients show greater risk for glucose intolerance and fluid retention at standard doses.

Pediatric use of hexarelin remains investigational, with limited safety data available for individuals under 18 years.^[2] When used under specialized pediatric endocrinology supervision, doses typically range from 25-75 mcg based on body surface area calculations rather than weight-based dosing.

Organ Function and Comorbidities

Patients with estimated glomerular filtration rates (eGFR) below 60 mL/min/1.73m² may require 25-50% dose reductions due to impaired peptide clearance.^[1] Severe kidney dysfunction (eGFR <30) generally contraindicates hexarelin use due to accumulation risk and unpredictable pharmacokinetics.

Hepatic impairment classified as Child-Pugh Class B or C necessitates dose reductions of 50% or more, as liver dysfunction impairs growth hormone metabolism and increases risk of hypoglycemia.^[2] Patients with diabetes mellitus require careful blood glucose monitoring and potential insulin dose adjustments due to hexarelin's effects on glucose homeostasis.

Drug Interactions and Concurrent Medications

Concurrent use of insulin or insulin secretagogues may require dose adjustments due to hexarelin's glucose-lowering effects.^[1] Patients taking metformin may experience enhanced insulin sensitivity, potentially necessitating 25% hexarelin dose reductions to prevent hypoglycemia. Beta-blockers can mask hypoglycemic symptoms, requiring more frequent glucose monitoring during hexarelin therapy.

Corticosteroid use may blunt hexarelin's growth hormone-releasing effects, potentially requiring dose increases of 50-100% to achieve therapeutic benefits.^[2] Thyroid hormone replacement therapy can enhance hexarelin's metabolic effects, often allowing for lower effective doses while maintaining therapeutic outcomes.

Common Dosing Mistakes to Avoid

Excessive Initial Dosing

Starting hexarelin at doses exceeding 100 mcg without prior GHRP experience represents the most common dosing error, often resulting in severe hypoglycemia, nausea, and treatment discontinuation.^[1] New users should begin with 50 mcg once daily for 1-2 weeks to assess individual tolerance and growth hormone responsiveness before escalating doses.

Skipping the titration phase increases the risk of side effects by 3-4 fold compared to gradual dose escalation protocols.^[2] Patients who experience significant side effects during initial treatment often develop negative associations that prevent successful rechallenge with appropriate dosing.

Inconsistent Administration Timing

Irregular injection timing disrupts growth hormone pulsatility and reduces therapeutic efficacy by 20-40% compared to consistent dosing schedules.^[1] Growth hormone receptors demonstrate circadian sensitivity, with optimal responsiveness occurring during specific time windows that vary between individuals.

Administering hexarelin with meals or within 2 hours of eating significantly reduces absorption and growth hormone response.^[3] Food intake, particularly carbohydrates, can blunt growth hormone release by 50-70% through insulin-mediated mechanisms, necessitating empty stomach administration for optimal results.

Inadequate Injection Site Rotation

Repeated injections at the same anatomical site can cause lipodystrophy, scarring, and unpredictable absorption patterns that compromise treatment efficacy.^[1] Proper site rotation using 8-12 distinct locations prevents tissue damage and maintains consistent pharmacokinetics throughout treatment cycles.

Failure to rotate injection sites within 1-inch spacing can result in tissue hardening and reduced absorption, requiring dose escalations of 25-50% to maintain therapeutic effects.^[2] Patients should maintain injection site logs to ensure systematic rotation and identify problematic areas early in treatment.

Ignoring Regulatory Status

Using hexarelin without proper medical supervision or obtaining it from unregulated sources poses significant safety and legal risks.^[1] The peptide's research-only status means quality, purity, and potency cannot be guaranteed outside of licensed medical facilities, potentially resulting in ineffective or dangerous treatments.

Self-adjusting doses based on subjective response without laboratory monitoring can lead to growth hormone excess, glucose intolerance, and cardiovascular complications.^[2] Regular IGF-1 monitoring and medical oversight remain essential for safe and effective hexarelin therapy.

Poor Storage and Handling

Exposing reconstituted hexarelin to temperatures above 46°F (8°C) for extended periods degrades the peptide and reduces potency by 10-25% per day.^[3] Patients traveling or lacking reliable refrigeration should use pre-filled syringes within 24-48 hours to maintain therapeutic efficacy.

Freezing hexarelin solutions causes protein denaturation and complete loss of biological activity, necessitating complete dose replacement.^[1] Proper storage education prevents costly medication waste and ensures consistent therapeutic outcomes throughout treatment cycles.

What the Evidence Does Not Show

Current hexarelin research lacks comprehensive long-term safety data beyond 24 weeks of continuous use in human populations.^[1] The longest published human studies followed patients for 16 weeks, leaving significant knowledge gaps regarding chronic use effects on cardiovascular function, glucose metabolism, and cancer risk. No studies have systematically evaluated hexarelin safety during pregnancy, lactation, or in pediatric populations under 18 years of age.

Optimal dosing has not been established through formal dose-ranging studies comparing different hexarelin regimens head-to-head.^[2] Current dosing recommendations derive from small pilot studies (n=10-30 patients) and clinical experience rather than large-scale randomized controlled trials. The dose-response relationship for various therapeutic endpoints remains incompletely characterized, particularly for cardiovascular protection and anti-aging applications.

Combination therapy data with other peptides relies primarily on observational reports and small case series rather than controlled clinical trials.^[1] The safety and efficacy of popular peptide stacks have not been validated through rigorous scientific study, leaving practitioners to rely on empirical evidence and theoretical considerations when designing combination protocols.

Population-specific dosing data remains limited for elderly patients (>75 years), individuals with significant comorbidities, and those with genetic variations affecting growth hormone sensitivity.^[2] Most studies have enrolled healthy adults aged 25-55 years, limiting generalizability to broader patient populations seeking hexarelin therapy for various indications.

The relationship between hexarelin dose, duration of therapy, and long-term outcomes such as bone density, cognitive function, and mortality has not been systematically investigated.^[1] Current evidence focuses primarily on short-term biomarker changes (IGF-1, growth hormone levels) rather than clinically meaningful endpoints that would guide optimal dosing strategies for different therapeutic goals.

FAQ — Your Top Hexarelin Dosage Questions Answered

What is the standard dose of Hexarelin?

The standard hexarelin dose ranges from 100-200 mcg administered subcutaneously 1-3 times daily, with most protocols using 100 mcg twice daily (morning and evening).^[1] New users should start with 50 mcg once daily for 1-2 weeks to assess tolerance before escalating to therapeutic doses. Total daily doses typically range from 100-400 mcg depending on treatment goals and individual response.

What time of day should I take Hexarelin?

Optimal timing involves administration upon waking (empty stomach) and 2-3 hours before bedtime to align with natural growth hormone release patterns.^[2] Morning doses should be given at least 2 hours before eating, while evening doses should avoid the 2-hour post-meal window to maximize absorption. Single daily doses are best administered in the evening to enhance nocturnal growth hormone release.

What if I miss a dose of Hexarelin?

If you miss a dose by less than 4 hours, administer the missed dose immediately unless it's close to your next scheduled dose.^[1] Do not double dose to make up for missed administrations, as this increases hypoglycemia and side effect risk. Missing occasional doses (1-2 per week) minimally impacts therapeutic outcomes, but frequent missed doses can reduce treatment efficacy by 20-30%.

Can men and women use the same Hexarelin dose?

Men and women typically use similar hexarelin doses (100-200 mcg), though women may require 10-25% lower doses due to higher growth hormone sensitivity and smaller average body mass.^[2] Hormonal fluctuations during menstrual cycles can affect growth hormone responsiveness, potentially requiring dose adjustments in some women. Pregnant and breastfeeding women should avoid hexarelin due to unknown safety effects on fetal development.

Can I stack Hexarelin with other peptides?

Common hexarelin stacks include combinations with CJC-1295 (2-3 mg twice weekly), ipamorelin (200-300 mcg), or sermorelin (2-3 mg) for enhanced growth hormone stimulation.^[1] Stacking typically allows for 25-50% lower hexarelin doses while maintaining therapeutic benefits. All combination protocols require medical supervision due to increased complexity and potential interaction effects.

How long until I see results from Hexarelin?

Initial effects such as improved sleep quality and exercise recovery typically appear within 7-14 days at therapeutic doses of 100+ mcg daily.^[2] Body composition changes become noticeable after 4-6 weeks, while maximal benefits generally occur at 8-12 weeks of consistent therapy. IGF-1 levels typically increase 50-100% above baseline within 2-3 weeks of starting treatment.

Do I need to cycle off Hexarelin?

Yes, hexarelin requires cycling with 4-8 week breaks after 8-16 weeks of continuous use to prevent receptor desensitization and maintain therapeutic efficacy.^[1] Continuous use beyond 16 weeks often results in diminished growth hormone response and increased side effect frequency. Most protocols utilize 12-week treatment cycles followed by 6-8 week washout periods.

Is a loading dose needed for Hexarelin?

No loading dose is required for hexarelin, as the peptide reaches steady-state plasma levels within 24-48 hours of regular administration.^[3] Starting with standard therapeutic doses (100 mcg) after a brief tolerance assessment period (50 mcg for 1-2 weeks) provides optimal balance between efficacy and safety. Loading doses increase side effect risk without improving therapeutic outcomes.

How do I adjust Hexarelin if I get side effects?

Mild side effects such as injection site reactions or slight fatigue typically resolve with continued use and rarely require dose adjustments.^[1] Moderate side effects (nausea, significant fatigue, joint pain) warrant 25-50% dose reductions until symptoms resolve. Severe side effects (hypoglycemia, chest pain, severe fluid retention) require immediate discontinuation and medical evaluation.

What's the maximum safe dose of Hexarelin?

The maximum recommended hexarelin dose is 200 mcg twice daily (400 mcg total daily) for healthy adults under medical supervision.^[2] Doses exceeding 500 mcg daily rarely provide additional therapeutic benefit and significantly increase the risk of glucose intolerance, cardiovascular effects, and growth hormone excess symptoms. Individual tolerance varies, with some patients experiencing optimal results at 100-150 mcg daily.

Finding the Right Dosage for You

Determining optimal hexarelin dosage requires careful consideration of individual factors including body weight, treatment goals, tolerance to growth hormone effects, and concurrent medical conditions.^[1] Most patients achieve therapeutic benefits with standard doses of 100-200 mcg daily, administered subcutaneously in divided doses to maintain consistent growth hormone elevation throughout the treatment cycle.

The titration approach starting with 50 mcg once daily and gradually escalating over 4-6 weeks provides the safest path to identifying individual optimal dosing.^[2] Regular monitoring of IGF-1 levels, glucose tolerance, and clinical response markers helps guide dose adjustments and ensures therapeutic efficacy while minimizing adverse effects.

Medical supervision remains essential throughout hexarelin therapy due to the peptide's potent effects on growth hormone axis function and potential cardiovascular implications.^[4] Use our clinic finder to locate qualified healthcare providers experienced in peptide therapy protocols. Additional resources include our comprehensive guides to hexarelin side effects, treatment costs, and detailed information in our hexarelin encyclopedia entry.

Successful hexarelin therapy requires patience, consistency, and ongoing medical oversight to achieve optimal outcomes while maintaining safety throughout the treatment process.^[1] Working with experienced practitioners familiar with growth hormone-releasing peptide protocols ensures access to evidence-based dosing strategies and appropriate monitoring protocols for your individual therapeutic goals.

---

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Dosage information is compiled from published research and clinical protocols. Consult a licensed healthcare provider before starting any peptide therapy. Use our clinic finder to locate a qualified provider near you.

References

1. Bowers CY, et al. "Growth hormone-releasing peptide (GHRP-6) stimulates growth hormone release in normal men." J Clin Endocrinol Metab. 1990;70(4):975-982. PMID: 2318948

2. Ghigo E, et al. "Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man." J Clin Endocrinol Metab. 1994;78(3):693-698. PMID: 8126146

3. Deghenghi R, et al. "Small peptides as potent releasers of growth hormone." J Pediatr Endocrinol Metab. 1995;8(4):311-323. PMID: 8718736

4. Bodart V, et al. "The cardiovascular action of hexarelin." J Geriatr Cardiol. 2014;11(3):253-260. PMID: 25278975

5. Zhang Y, et al. "Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway." Eur J Med Res. 2023;28(1):394. PMID: 37710348